title: Risk factors for rituximab-induced interstitial lung diseases in patients with malignant lymphoma.
authors.forename: Seung-Ick
authors.initials: SI
authors.lastname: Cha
authors.forename: Keum-Ju
authors.initials: KJ
authors.lastname: Choi
authors.forename: Kyung-Min
authors.initials: KM
authors.lastname: Shin
authors.forename: Jaekwang
authors.initials: J
authors.lastname: Lim
authors.forename: Seung-Soo
authors.initials: SS
authors.lastname: Yoo
authors.forename: Jaehee
authors.initials: J
authors.lastname: Lee
authors.forename: Shin-Yup
authors.initials: SY
authors.lastname: Lee
authors.forename: Chang-Ho
authors.initials: CH
authors.lastname: Kim
authors.forename: Jae-Yong
authors.initials: JY
authors.lastname: Park
mesh_terms: D000367:Age Factors; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D015999:Multivariate Analysis; D012189:Retrospective Studies; D012307:Risk Factors; D000069283:Rituximab; D012720:Severity of Illness Index
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab